Renopharm Ltd. Is a privately held company. Shareholders are a small and homogenous group of investors, interested in finding new funds (investors) against equity.
Renopharm Ltd. is currently seeking to raise 5 Mio USD in order to pursue at least three leads and to enter the clinical phase with these undertakings. A key investor, who brings at least 2 Mio USD, would be invited to join the company’s board.

Renopharm Ltd. combines novel science with a business orientated mindset. Renopharm Ltd. is a highly professional run company, which minimizes the risks for investors.

In consideration of the enormous market potential, matching Renopharm's technology, we see a tremendous value creation potential mid-term.

The business concept of Renopharm Ltd. which envisages several partnerships with industrial partners, will allow partial exits and therefore, generic cash flow, such achieved milestones would minimize future shareholder's dilution and enhance value to investors in a significant manner.

Interested investors or industrial partners, please contact peter@renopharm.com